Advertisement

Topics

Linagliptin improved albuminuria but effect on eGFR and CV risk in patients with diabetes

20:00 EDT 13 Jun 2019 | AAAS

(ERA-EDTA) In the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin. The antidiabetes drug reduced albuminuria and HbA1c in all patients, but did not affect the cardiovascular (CV) risk over 2.2 years. Additionally, it had no impact on the glomerular filtration rate (eGFR), a marker of kidney function.

Original Article: Linagliptin improved albuminuria but effect on eGFR and CV risk in patients with diabetes

NEXT ARTICLE

More From BioPortfolio on "Linagliptin improved albuminuria but effect on eGFR and CV risk in patients with diabetes"

Advertisement
Quick Search
Advertisement
Advertisement